The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Dec 2016
Randomized Controlled Trial Multicenter Study Comparative StudyExenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce glycaemia and weight, and improve cardiovascular risk factors via different mechanisms. We aimed to compare the efficacy and safety of co-initiation of the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin with exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled by metformin. ⋯ AstraZeneca.
-
Lancet Diabetes Endocrinol · Dec 2016
Randomized Controlled Trial Multicenter StudyEffectiveness of activity trackers with and without incentives to increase physical activity (TRIPPA): a randomised controlled trial.
Despite the increasing popularity of activity trackers, little evidence exists that they can improve health outcomes. We aimed to investigate whether use of activity trackers, alone or in combination with cash incentives or charitable donations, lead to increases in physical activity and improvements in health outcomes. ⋯ Ministry of Health, Singapore.